RAPT Rapt Therapeutics, Inc.

20.70-0.54 (-2.54%)
Close: November 21, 2019

Quote

Previous Close
$20.70
Day Range
$19.69-$21.50
52 Week Range
$11.85-$42.00
Volume
21,089
Avg Volume
115,289
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$440.49M
Enterprise Value (EV)
$549.30M
PE Ratio
-
EV/EBITDA
-15.38
Price/Sales
-
Price/Book
-
PEG Ratio
-

Financials

Revenue
-
Gross Profit
-$1.24M
EBITDA
-$35.71M
EPS, ttm
-
Profit Margin
-
Revenue/Employee
-
Next Earnings Date
-
Debt to Equity
-167%
Debt
$172.60M
Cash
$63.80M
Net Debt
$108.80M

Performance

Beta
-2.66
200 Day Moving Avg
$18.48
50 Day Moving Avg
$18.48
52 Week Change
63.38%
YTD Change
60.84%
1 Month Change
63.38%
3 Month Change
63.38%
6 Month Change
63.38%
1 Year Change
63.38%
2 Year Change
63.38%
5 Year Change
63.38%

Share Count

Shares Outstanding
21.3M
Float
5.0M
Restricted Shares
16.3M
Restricted Shares, %
76.51%

Rapt Therapeutics, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Brian Russell Wong

Website: http://www.flxbio.com

Description: Rapt Therapeutics, Inc. operates as a clinical stage immunology-based biopharmaceutical company. It focuses on discovering, developing and commercializing oral small molecule therapies for patients in oncology and inflammatory diseases.. The company was founded in 2015 and is headquartered in South San Francisco, CA.

Employees: 64